. Author manuscript; available in PMC: 2011 Apr 1.

Published in final edited form as: Clin Pharmacol Ther. 2010 Mar 3;87(4):445–451. doi: 10.1038/clpt.2009.291

Table 3.

Characteristics of replication cohorts, stratified by CALU SNP rs339097

	Replication Cohort #1		Replication Cohort #2

Characteristic	rs339097 GG or AG (n = 21)	rs339097 AA (n= 475)	rs339097 GG or AG (n = 52)	rs339097 AA (n= 142)

Therapeutic warfarin dose (mg/day, mean^§ ± SD )	6.5 ± 1.4	4.8 ± 1.6^**	6.3 ± 2.3	5.7 ± 2.3

Age (years, mean ± SD)	57 ± 19	62 ± 15	58 ± 15	56 ± 16

Race (%)
African-American	86%	11%^**	100%	100%
Caucasian	10%	85%	0%	0%
Other	5%	4%	0%	0%

BSA (m², mean ± SD)	2.0 ± 0.2	2.0 ± 0.3	2.0 ± 0.4	2.1 ± 0.3

VKORC1 -1639 A^†	10%	37%	12%	20%

CYP2C9*2^†	2%	12%	2%	6%

CYP2C9*3^†	2%	6%	2%	1%

Current smoker	29%	14%^*	10%	21%

Current amiodarone use	16%	2%^*	2%	2%

BSA = Body surface area; CYP2C9*2 = Cytochrome P450 2C9*2; CYP2C9*3 = Cytochrome P450*3; SD = standard deviation; DVT = deep venous thrombosis; PE = pulmonary embolus; Comparisons to heterozygotes/homozygotes for rs339097:

p<0.05;

^**

p<0.01;

^†

represented as percentage with minor allele;

^§

geometric mean